Epidemiological study of Klebsiella spp. uropathogenic strains producing extended-spectrum β-lactamase in a Tunisian university hospital, 2009;Epidémiologie des souches de Klebsiella spp. uropathogènes productrices de β-lactamases à spectre élargi dans un hôpital universitaire Tunisien, 2009

Pathologie Biologie

Volumn 60, Issue 2, 2012, Pages

  Ben Haj Khalifa, A ^a   Khedher, M ^a  

^a Tahar Sfar University Hospital   (Tunisia)

Author keywords

3rd generation cephalosporins; Extended spectrum lactamase; Klebsiella spp; Quinolone; Resistance

Indexed keywords

CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; HUMAN; KLEBSIELLA; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; PREVALENCE; RETROSPECTIVE STUDY; TUNISIA; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION;

BETA-LACTAMASES; CROSS INFECTION; FEMALE; HOSPITAL UNITS; HOSPITALS, UNIVERSITY; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; TUNISIA; URINARY TRACT INFECTIONS;

EID: 84859424004     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.11.003     Document Type: Article

References (50)

1. Coque T., Baquerot F., Canton R. Increasing prevalence of ESBL - producing Enterobacteriaceae in Europe. Eurosurveillance 2008, 13:1-11.
2. Pitout J.D., Laupland K. Extended spectrum betalactamase-producing Enterobacteriacaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
3. Pitout J.D., Nordmann P., Laupland K., Poirel L. Emergence of Enterobacteriaceae producing extended spectrum betalacatamases (ESBL) in the community. J Antimicrob Chemother 2005, 56:52-59.
4. Kliebe C., Nies B.A., Meyer J.F., Tolxdorff-Neutzling R.M., Wieddemann B. Evolution of plasmid-coded resistance to broad spectrum cephalosporins. Antimicrob Agents Chemother 1985, 28:302-307.
5. Jacob G., Bush K. Amino acid sequences for TEM. SHV and OXA extended spectrum and inhibitor resistant β-lactamases 2006, http://www.labey.org/studies/ [last accessed 07/30/2006].
6. Moinard D. Examen cytobactériologique des urines. Bactériologie médicale, 1987, 53-60. Simep, Paris. B. Carbonnelle, F. Denis, A. Marmonier, G. Pinon, R. Vargues (Eds.).
7. Weber P., Dib C., Durand C., Moniot-Ville N. évaluation de la sensibilité à la lévofloxacine des souches isolées d'infections urinaires basses communautaires. Pathol Biol 2005, 53:125-128.
8. Hooton T.M. Pathogenesis of urinary tract infection: an update. J Antimicrob Chemother 2000, 46:S1-7.
9. CMIT, infections urinaires. CMIT ? In: E. Pilly (Ed.), Montmorency: 2M2 Ed; 2003:p 196-201.
10. Tlamçani Z., Ellaia K., Benomar A., Kabbaj H., Alaoui A.E., Seffar M. La résistance aux fluoroquinolones chez des souches de Klebsiella spp. productrices de bêtalactamase à spectre étendu isolées dans les urines. Ann Biol Clin 2009, 67:553-556.
11. Romero E.D.V., Padilla T.P., Hernández A.H., Grande R.P., Vázquez M.F., García I.G., et al. Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum β-lactamases. Diagn Microbiol Infect Dis 2007, 59:433-437.
12. Belmonte O., Drouet D., Alba J., Moiton M.P., Kuli B., Lugagne-Delpon N., et al. évolution de la résistance des entérobactéries aux antibiotiques sur l'ile de la Réunion : émergence des bêta-lactamases à spectre élargi. Path biol 2010, 58:18-24.
13. Diekema D.J., Boots Miller B.J., Vaughn T.E., Woolson R.F., Yankey J.W., Ernst E.J., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004, 37:78-85.
14. Hirakata Y., Matsuda J., Miyazaki Y., Kamihira S., Kawakami S., Miyazawa Y., et al. Regional variation in the prevalence of extended-spectrum β-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998--2002). Diagn Microbiol Infect Dis 2005, 52:323-329.
15. Buré A., Legrand P., Arlet G., Jarlier V., Paul G., Philippon A. Dissemination in five French hospitals of Klebsiella pneumoniae serotype K25 harbouring a new transferable resistance to third generation cephalosporins and aztreonam. Eur J Clin Microbiol Infect Dis 1988, 7:780-782.
16. Brun-Buison C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third-generation cephalosporins during a nosocomial outbreak of multi-resistant Klebsiella pneumoniae. Lancet 1987;ii:302-6.
17. De Champs C., Sirot D., Chanal C., Poupart M.C., Dumas M.P., Sirot J. Concomitant dissemination of three extended-spectrum β-lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrobial Chemother 1991, 27:441-447.
18. Sirot D.L., Goldstein F.W., Soussy C.J., Courtieu A.L., Husson M.O., Lemozy J., et al. Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob Agents Chemother 1992, 36:1677-1681.
19. Sirot D. Extended-spectrum β-lactamases. J Antimicrob Chemother 1995, 36(Suppl. A):19-34.
20. Bingen E.H., Desjardins P., Arlet G., Bourgeois F., Mariani-Kurkdjian P., Lambert-Zechovsky N.Y., et al. Molecular epidemiology of plasmid spread among extended broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital. J Clin Microbiol 1993, 31:179-184.
21. Jacoby G.A., Medeiros A.A. More extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991, 35:1697-1704.
22. Philippon A., Labia R., Jacoby G.A. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989, 33:1131-1136.
23. Sirot D. Extended-spectrum plasmid-mediated beta-lactamases. J Antimicrob Chemother 1995, 36(Suppl. A):19-34.
24. Jacoby G.A., Sutton L. Properties of plasmids responsible for production of extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991, 35:164-169.
25. Goldstein F.W., Péan Y., Rosato A., Gertner J., Gutmann L. Characterization of ceftriaxone-resistant Enterobacteriaceae: a multicentre study in 26 French hospitals Vigil'Roc Study Group. J Antimicrob Chemother 1993, 32:595-603.
26. Mariotte S., Nordmann P., Nicolas M.H. Extended-spectrum β-lactamase in Proteus mirabilis. J Antimicrob Chemother 1994, 33:925-935.
27. Arlet G., Sanson-le Pors M.J., Rouveau M., Fournier G., Marie O., Schlemmer B., et al. Outbreak of nosocomial infections due to Klebsiella pneumonia producing SHV-4 beta-lactamase. Eur J Clin Microbiol Infect Dis 1990, 9:797-803.
28. Brun-Buisson C., Legrand P., Rauss A., Richard C., Montravers F., Besbes M., et al. Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann Intern Med 1989, 110:873-881.
29. Johnson A.P., Weinbren M.J., Ayling-Smith B., Du Bois S.G.B., George R.C. Outbreak of infection in two UK hospitals caused by a strain of Klebsiella pneumoniae resistant to cefotaxime and ceftazidime. J Hosp Infect 1992, 20:97-103.
30. Meyer K.S., Urban C., Eagan J.A., Berger B.J., Rahal J.J. Nosocomial outbreak of Klebsiella pneumoniae resistant to late-generation cephalosporins. Ann Inter Med 1993, 119:353-358.
31. Zogheib E, Dupont H. Entérobactéries multirésistantes. Conférences d'actualisation de la SFAR 2005:153-5.
32. Quinn J.P., Miyashiro D., Sahm D., Flamm R., Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989, 33:1451-1456.
33. Paterson D.L., Ko W.C., Von Gottberg A., Casellas J.M., Mulazimoglu L., Klugman K.P., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001, 39:2206-2212.
34. Babini G.S., Livermore D.M. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997--1998. J Antimicrob Chemother 2000, 45:183-189.
35. Hernández J.R., Martínez-Martínez L., Cantón R., Coque T.M., Pascual A. Nationwide Study of Escherichia coli and K. pneumonia producing extended-spectrum â-lactamases in Spain. Antimicrob Agents Chemother 2005, 49:2122-2125.
36. Blanco J.E., Blanco M., Mora A., Blanco J. Prevalence of bacterial resistance to quinolones and other antimicrobial among avian Escherichia coli strains isolates from septicemic and healthy chickens in Spain. J Clin Microbiol 1997, 35:2184-2185.
37. Garau J., Xercavins M., Rodriguez-Carballeira M., Gomez-Vera J.R., Coll I., Vidal D. Emergence and dissemination of quinolone-resistance Escherichia coli in the community. Antimicrob Agents Chemother 1999, 43:2736-2741.
38. Smith K.E., Besser J.M., Hedberg C.W., Leano F.T., Bender J.B., Wicklund J.H., et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998 Investigation Team. N Engl J Med 1999, 340:1525-1532.
39. Thomson K.S., Sanders C.C. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. J Antimicrob Chemother 1998, 42:179-187.
40. Sheng WH, Chen YC, Wang JT, Chang SC, Luh KT, Hsieh WC. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis 2002;43:141-7.
41. Samaha-Kfoury J.N., Kanj S.S., Araj G.F. In vitro activity of antimicrobial agents against extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. Am J Infect Control 2005, 33:134-136.
42. Nordmann P, Mammeri H. Résistance plasmidique aux quinolones. Antibiotiques 2007;9:246-53.
43. Martinez-Martinez L., Pascual A., Jacoby G.A. Quinolone resistance from a transferable plasmid. Lancet 1998, 351:797-799.
44. Robicsek A., Strahilevitz J., Jacoby G.A. Fluoroquinolone modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006, 12:83-88.
45. Lavilla S., González-López J.J., Sabaté M., García-Fernández A., Larrosa M.N., Bartolomé R.M. Prevalence of qnr genes among extended-spectrumß-lactamase-producing enterobacterial isolatesin Barcelona Spain. J Antimicrob Chimother 2008, 61:291-295.
46. DiPersio J.R., Deshpande L.M., Biedenbach D.J., Toleman M.A., Walsh T.R., Jones R.N. Evolution and dissemination of extended-spectrum (-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis 2005, 51:1-7.
47. Arslan H., Azap O.K., Ergonul O., Timurkaynak F. Urinary tract infection risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from communuty acquired urinary tract infections Study Group in Turkey. J Antimicrob Chemother 2005, 56:914-918.
48. Nickel JC. Management of urinary tract infections: historical perspective and current strategies: part 2 - Modern management. J Urol 2005:173:27-32.
49. Grude N., Tveten Y., Jenkins A., Kristiansen B.E. Uncomplicated urinary tract infections. Bacterial findings and efficacy of empirical antibacterial treatment. Scand J Prim Health Care 2005, 23:115-119.
50. Komp Lindgren P., Marcusson L.L., Sandvang D., Frimodt-Moller N., Hughes D. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. AAC 2005, 49:2343-2351.